a Faculty of Literature and Human Sciences , Catholic Institute of Toulouse , Toulouse , France.
b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.
Psychol Health Med. 2019 Aug;24(7):781-787. doi: 10.1080/13548506.2019.1574354. Epub 2019 Feb 4.
The aim of this study was to measure the prevalence of FCR among a sample of French lymphoma survivors and to determine factors associated with clinical levels of FCR. The study was conducted with two cross-sectional measures: sociodemographic and anxiety, depression as well as health-related quality of life (HRQoL) scores were measured at the baseline of the post-cancer period and FCR was evaluated during the first 3 years of survivorship. The prevalence of clinical levels of FCR (≥13) was evaluated by the Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) among non- and Hodgkin lymphoma survivors undergoing prior first-line chemotherapy. Among 108 lymphoma survivors with an average follow-up of 1.6 years (range 0.3-3.0 years), clinical levels of FCR (≥13) were observed for 44.4% (n = 48). Multivariate analysis indicated that baseline anxiety and low quality of life were related to clinically significant FCR levels.
本研究旨在测量法国淋巴瘤幸存者中 FCR 的患病率，并确定与 FCR 临床水平相关的因素。该研究采用了两种横断面测量方法：在癌症后时期的基线测量社会人口统计学和焦虑、抑郁以及健康相关生活质量（HRQoL）评分，在幸存者生存的前 3 年内评估 FCR。通过对先前接受一线化疗的非霍奇金淋巴瘤幸存者进行 Fear of Cancer Recurrence Inventory - Short Form（FCRI-SF）评估，评估 FCR 临床水平（≥13）的患病率。在 108 名平均随访 1.6 年（范围 0.3-3.0 年）的淋巴瘤幸存者中，观察到 44.4%（n=48）的 FCR 临床水平（≥13）。多变量分析表明，基线焦虑和低生活质量与临床显著的 FCR 水平相关。
